Peapack Gladstone Financial Corp Has $24.27 Million Stake in Bristol Myers Squibb Company $BMY

Peapack Gladstone Financial Corp trimmed its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 449,854 shares of the biopharmaceutical company’s stock after selling 27,703 shares during the period. Peapack Gladstone Financial Corp’s holdings in Bristol Myers Squibb were worth $24,266,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Northwestern Mutual Investment Management Company LLC increased its holdings in Bristol Myers Squibb by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock valued at $3,509,000 after purchasing an additional 172 shares in the last quarter. ESG Planning DBA Harper Investing increased its holdings in Bristol Myers Squibb by 1.3% during the 4th quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 180 shares in the last quarter. Novem Group increased its holdings in Bristol Myers Squibb by 2.9% during the 4th quarter. Novem Group now owns 6,402 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 183 shares in the last quarter. Dominguez Wealth Management Solutions Inc. increased its holdings in Bristol Myers Squibb by 0.8% during the 4th quarter. Dominguez Wealth Management Solutions Inc. now owns 22,404 shares of the biopharmaceutical company’s stock valued at $1,208,000 after purchasing an additional 185 shares in the last quarter. Finally, McLean Asset Management Corp increased its holdings in Bristol Myers Squibb by 3.1% during the 4th quarter. McLean Asset Management Corp now owns 6,465 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 192 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMS reported encouraging late-stage data for mezigdomide, saying the experimental CELMoD cut the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma. That is the kind of readout investors watch for because it strengthens the case for a future commercial opportunity. Article Title
• Positive Sentiment: The company also highlighted mezigdomide data in a business update, reinforcing optimism around its broader oncology pipeline and suggesting Celgene-derived assets continue to support long-term growth prospects. Article Title
• Positive Sentiment: Bristol Myers Squibb said it is backing a new cell-therapy combination in an early gastrointestinal cancer trial, which adds another potential pipeline catalyst and underscores continued investment in high-value cancer programs. Article Title
• Positive Sentiment: BMS also announced a strategic partnership with Anthropic to use Claude across research, clinical development, manufacturing, commercial, and corporate functions, a move that could improve productivity and speed decision-making over time. Article Title

Bristol Myers Squibb Stock Down 0.0%

NYSE:BMY opened at $57.17 on Monday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm has a market capitalization of $116.75 billion, a P/E ratio of 16.06, a P/E/G ratio of 0.16 and a beta of 0.24. The stock’s fifty day simple moving average is $58.32 and its 200-day simple moving average is $56.32.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the company earned $1.80 EPS. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts expect that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Cantor Fitzgerald increased their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, April 8th. Barclays assumed coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective on the stock. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Sunday, April 19th. Finally, Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $61.31.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.